$233.4 M

PETX Mkt cap, 14-Jun-2018

$4 M

Aratana Therapeutics Revenue Q1, 2018
Aratana Therapeutics Gross profit (Q1, 2018)3.5 M
Aratana Therapeutics Gross profit margin (Q1, 2018), %86.7%
Aratana Therapeutics Net income (Q1, 2018)-8.5 M
Aratana Therapeutics EBIT (Q1, 2018)-7.8 M
Aratana Therapeutics Cash, 31-Mar-201866.4 M

Aratana Therapeutics Financials

Aratana Therapeutics Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

123 k767 k678 k38.6 m25.6 m

Revenue growth, %

524%(12%)5586%

Cost of goods sold

108 k365 k3.1 m16.4 m

Gross profit

15 k313 k35.4 m9.2 m

Gross profit Margin, %

12%46%92%36%

R&D expense

15.1 m

General and administrative expense

28.9 m

Operating expense total

70 m

Depreciation and amortization

350 k

EBIT

(41.9 m)(41.6 m)(89.5 m)(30.8 m)(44.5 m)

EBIT margin, %

(34102%)(5425%)(13200%)(80%)(174%)

Interest expense

432 k1.6 m3.4 m3.5 m

Interest income

75 k189 k385 k449 k

Pre tax profit

(19.7 m)(85.8 m)(33.6 m)(47.5 m)

Income tax expense

15.5 m1.7 m1.7 m

Net Income

(26.2 m)(38.8 m)(84.1 m)(33.6 m)(47.5 m)

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

176 k300 k43 k156 k230 k229 k172 k38 m40 k3.8 m5.2 m4 m

Cost of goods sold

110 k109 k138 k19 k1.7 m286 k3.1 m3.7 m536 k

Gross profit

46 k121 k91 k153 k36.3 m(246 k)701 k1.5 m3.5 m

Gross profit Margin, %

29%53%40%89%95%(615%)18%28%87%

R&D expense

3.6 m4.3 m6.1 m6.2 m6.1 m6.2 m10.7 m5.3 m5.3 m4.7 m3.7 m2.2 m

General and administrative expense

4.6 m4.4 m3.9 m4.2 m4.9 m5 m6.6 m6.1 m6.9 m7.5 m6.9 m7.7 m

Operating expense total

9.4 m9.8 m10.6 m11 m11.6 m55.2 m17.4 m16.1 m12.7 m15.6 m14.7 m11.9 m

Depreciation and amortization

130 k

EBIT

(9.2 m)(9.5 m)(10.5 m)(10.9 m)(11.3 m)(55 m)(17.3 m)22 m(12.6 m)(11.8 m)(9.6 m)(7.8 m)

EBIT margin, %

(5240%)(3168%)(24488%)(6963%)(4933%)(24021%)(10035%)58%(31535%)(312%)(186%)(194%)

Interest expense

328 k218 k222 k218 k217 k226 k849 k846 k859 k860 k871 k853 k

Interest income

14 k13 k31 k71 k43 k33 k77 k83 k116 k85 k88 k141 k

Pre tax profit

(9.8 m)(9.6 m)(10.7 m)(9 m)(8.3 m)(55.2 m)(18.1 m)21.2 m(13.4 m)

Income tax expense

627 k335 k601 k271 k360 k758 k

Net Income

(9.2 m)(9.3 m)(28.6 m)(8.8 m)(8 m)(54.4 m)(18.1 m)21.2 m(13.4 m)(12.6 m)(10.4 m)(8.5 m)

Aratana Therapeutics Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

41.1 m9.8 m26.8 m87.3 m66.9 m

Accounts Receivable

352 k60 k87 k2.4 m

Inventories

274 k427 k1.3 m11.1 m13.6 m

Current Assets

48.5 m99.9 m89 m101.5 m85.2 m

PP&E

98 k620 k2.6 m1.9 m1.2 m

Goodwill

20.8 m41.4 m39.8 m39.4 m41.3 m

Total Assets

115.5 m207.9 m147.1 m151.4 m135.2 m

Accounts Payable

2.3 m1.5 m1.4 m7.4 m7.5 m

Short-term debt

Current Liabilities

16.9 m9.5 m5.7 m34.7 m35.5 m

Long-term debt

Total Liabilities

61 m55.1 m

Additional Paid-in Capital

112.5 m255 m263.9 m286.9 m321.6 m

Retained Earnings

(68 m)(152 m)(185.6 m)(233.3 m)

Total Equity

86 m181.8 m101.6 m90.4 m80.1 m

Financial Leverage

1.3 x1.1 x1.4 x1.7 x1.7 x

Quarterly

USDQ3, 2013Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

46.2 m56.8 m30.2 m12.6 m13.5 m13.8 m108.8 m100.8 m67.5 m78.8 m66.4 m

Accounts Receivable

90 k115 k148 k134 k11 k17 k15 k3.5 m4.9 m2.4 m

Inventories

203 k645 k882 k1.2 m2.4 m2.6 m5.6 m9.1 m7 m14 m

Current Assets

52.6 m110.5 m89.4 m85.7 m75.3 m77.1 m113.7 m110.9 m81.9 m98.8 m84.6 m

PP&E

21 k741 k614 k1.6 m2.3 m2.4 m2.3 m2.1 m1.6 m1.5 m1 m

Goodwill

37.1 m39.6 m40.2 m40.2 m40.5 m40 m40.3 m39.6 m40.5 m41.7 m

Total Assets

52.7 m221.3 m193.3 m186.9 m133.4 m136 m168.9 m167.3 m134.7 m152.7 m134.7 m

Accounts Payable

816 k1.9 m2.1 m1.7 m1.2 m6.4 m7.3 m5.1 m1.2 m1.9 m1.9 m

Current Liabilities

5.1 m9.9 m5.7 m20.9 m5.4 m8.6 m21.1 m21.4 m30.7 m23.3 m25.1 m

Total Liabilities

8.8 m28.3 m21.8 m21.8 m20.5 m49.1 m59.2 m56.1 m53.6 m52.7 m39 m

Additional Paid-in Capital

77.4 m253.1 m257.4 m259.5 m261.8 m266.2 m268.4 m283 m290.1 m318 m338.5 m

Retained Earnings

(55.1 m)(76.7 m)(84.7 m)(139.2 m)(170.1 m)(148.9 m)(162.3 m)(198.4 m)(208.8 m)(235.1 m)

Total Equity

43.8 m193 m171.5 m165.1 m113 m86.9 m109.6 m111.2 m81.1 m100 m95.6 m

Financial Leverage

1.2 x1.1 x1.1 x1.1 x1.2 x1.6 x1.5 x1.5 x1.7 x1.5 x1.4 x

Aratana Therapeutics Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(4.3 m)(38.8 m)(84.1 m)(33.6 m)(47.5 m)

Depreciation and Amortization

395 k2 m1.8 m379 k1.2 m

Accounts Receivable

(102 k)281 k(27 k)(2.3 m)

Inventories

(372 k)(879 k)(15 m)(3.2 m)

Accounts Payable

1.5 m(1.1 m)(117 k)6.2 m62 k

Cash From Operating Activities

(16.2 m)(32.2 m)(38.5 m)(11.3 m)(38.2 m)

Purchases of PP&E

(1 k)

Cash From Investing Activities

(29.2 m)(100.1 m)33.7 m57.3 m(5.8 m)

Cash From Financing Activities

72.5 m101 m21.9 m14.6 m23.5 m

Interest Paid

357 k942 k

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Net Income

(11.4 m)(9.2 m)(18.4 m)(28.6 m)(8.8 m)(8 m)(71.2 m)(18.1 m)3.1 m(10.2 m)(12.6 m)(23 m)(8.5 m)

Depreciation and Amortization

9 k566 k1.2 m1.9 m520 k1.1 m1.6 m244 k493 k738 k392 k605 k249 k

Accounts Receivable

125 k(116 k)174 k227 k194 k208 k49 k43 k45 k(3.5 m)(4.8 m)(32 k)

Inventories

(70 k)(69 k)(148 k)(218 k)(455 k)(746 k)(1 m)(2.8 m)(5.8 m)2.1 m4.2 m(376 k)

Accounts Payable

36 k(1.3 m)(1.7 m)(763 k)630 k213 k(274 k)5 m5.9 m3.7 m(6.2 m)(5.5 m)(5.6 m)

Cash From Operating Activities

(10.9 m)(8.2 m)(15.9 m)(22.8 m)(9 m)(17.8 m)(28.1 m)(13.4 m)23.3 m5.2 m(18.4 m)(29.9 m)(13.2 m)

Purchases of PP&E

(14 k)

Cash From Investing Activities

375 k(13.4 m)(13.1 m)32.5 m23.6 m34.6 m442 k58.7 m56.9 m(2.5 m)(3.5 m)249 k

Cash From Financing Activities

42.7 m57.3 m56.2 m101 m(3 m)(3 m)(2.7 m)(3 m)1 k11.9 m1.2 m24.9 m12.5 m

Interest Paid

161 k386 k413 k584 k206 k415 k628 k721 k1.4 m2.2 m733 k1.5 m728 k

Aratana Therapeutics Ratios

USDY, 2018

Financial Leverage

1.4 x
Report incorrect company information